Table 2.
Associated comorbidities of participants.
| Characteristic | Total (n = 77) | Control (n = 38) | MAFLD (n = 39) | p-Value |
|---|---|---|---|---|
| Diabetes Mellitus Type 2 (yes), n (%) | 15 (19.48) | 0 (0) | 15 (38.46) | <0.001 |
| Impaired fasting glucose (yes), n (%) | 5 (6.49) | 2 (5.26) | 3 (7.69) | >0.99 |
| Hypertension (yes), n (%) | 37 (48.05) | 6 (15.79) | 31 (79.49) | <0.001 |
| Chronic kidney disease (yes), n (%) | 1 (1.3) | 0 (0) | 1 (2.56) | >0.99 |
| Ischemic heart disease (yes), n (%) | 4 (5.19) | 0 (0) | 4 (10.26) | 0.115 |
| History of cerebrovascular accident (yes), n (%) | 2 (2.6) | 0 (0) | 2 (5.13) | 0.494 |
| History of transient ischemic attack (yes), n (%) | 1 (1.3) | 0 (0) | 1 (2.56) | >0.99 |
| Irritable bowel syndrome (yes), n (%) | 7 (9.09) | 4 (10.53) | 3 (7.69) | 0.711 |
| Gastroesophageal reflux disease (yes), n (%) | 2 (2.6) | 1 (2.63) | 1 (2.56) | >0.99 |
| Chronic pancreatitis (yes), n (%) | 1 (1.3) | 0 (0) | 1 (2.56) | >0.99 |
| Fibromyalgia (yes), n (%) | 1 (1.3) | 0 (0) | 1 (2.56) | >0.99 |
MAFLD—Metabolic-associated fatty liver disease.